|
Nov 1
|
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
|
|
Nov 1
|
Company News for Nov 1, 2024
|
|
Nov 1
|
Bristol-Myers Squibb Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Nov 1
|
Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic ...
|
|
Nov 1
|
Q3 2024 Bristol-Myers Squibb Co Earnings Call
|
|
Oct 31
|
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
|
|
Oct 31
|
Bristol Myers Screams To A Year-High After Walloping Profit Expectations
|
|
Oct 31
|
A promising schizophrenia drug showed mixed results. What does that mean for patients?
|
|
Oct 31
|
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
|
|
Oct 31
|
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
|
|
Oct 31
|
Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat.
|
|
Oct 31
|
Bristol Myers Squibb stock rises, Merck moves lower. Here's why.
|
|
Oct 31
|
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
|
|
Oct 31
|
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics
|
|
Oct 31
|
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
|
|
Oct 31
|
Bristol-Myers hikes annual earnings guidance as Q3 exceeds expectations; shares up
|
|
Oct 31
|
Bristol Myers earnings beat expectations, driven by sales of older drugs
|
|
Oct 31
|
Bristol Myers: Q3 Earnings Snapshot
|
|
Oct 31
|
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
|
|
Oct 3
|
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
|